Tonix Pharmaceuticals Holding Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
142
- Stock Symbol
-
TNXP
- Investments
-
7
- Share Price
-
$2.88
- (As of Monday Closing)
Tonix Pharmaceuticals Holding General Information
Description
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Contact Information
Website
www.tonixpharma.comCorporate Office
- 26 Main Street
- Suite 101
- Chatham, NJ 07928
- United States
Corporate Office
- 26 Main Street
- Suite 101
- Chatham, NJ 07928
- United States
Tonix Pharmaceuticals Holding Timeline
Tonix Pharmaceuticals Holding Stock Performance
As of 16-Nov-2026, Tonix Pharmaceuticals Holding’s stock price is $2.88. Its current market cap is $56M with 19.4M shares.
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.88 | $3.01 | $2.81 - $20.56 | $56M | 19.4M | 802K | -$12.22 |
Tonix Pharmaceuticals Holding Financials Summary
As of 30-Sep-2026, Tonix Pharmaceuticals Holding has a trailing 12-month revenue of $43M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (7,909) | 10,120 | 42,097 | 17,858 |
| Revenue | 43,046 | 13,107 | 10,094 | 7,768 |
| EBITDA | (184,164) | (126,153) | (125,403) | (112,367) |
| Net Income | (180,985) | (124,021) | (130,036) | (116,658) |
| Total Assets | 242,426 | 277,171 | 162,890 | 154,457 |
| Total Debt | 1,253 | 1,309 | 8,119 | 9,813 |
Tonix Pharmaceuticals Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Tonix Pharmaceuticals Holding Comparisons
Industry
Financing
Details
Tonix Pharmaceuticals Holding Competitors (38)
One of Tonix Pharmaceuticals Holding’s 38 competitors is Seres Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Seres Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Cognition Therapeutics | Formerly VC-backed | New York, NY | ||||
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| Neurelis | Venture Capital-Backed | San Diego, CA | ||||
| Dogwood Therapeutics | Formerly VC-backed | Alpharetta, GA |
Tonix Pharmaceuticals Holding Patents
Tonix Pharmaceuticals Holding Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025199179-A2 | Oxytocin peptide analogs | Pending | 18-Mar-2024 | ||
| WO-2025199179-A3 | Oxytocin peptide analogs | Pending | 18-Mar-2024 | ||
| WO-2025160302-A1 | Cyclobenzaprine treatment for acute stress reaction or acute stress disorder | Pending | 25-Jan-2024 | ||
| WO-2025137348-A1 | Cyclobenzaprine hcl for use in treating fibromyalgia with early onset response and favorable tolerability and side effect profile | Inactive | 19-Dec-2023 | ||
| US-20250322926-A1 | Early onset response, favorable tolerability, and side effect profile in the treatment of fibromyalgia | Pending | 19-Dec-2023 | G16H20/10 |
Tonix Pharmaceuticals Holding Signals
Tonix Pharmaceuticals Holding Investments & Acquisitions (7)
Tonix Pharmaceuticals Holding’s most recent deal was a Corporate Asset Purchase with Dr. Reddy's (Neurology Migraine Products) for . The deal was made on 30-Jun-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dr. Reddy's (Neurology Migraine Products) | 30-Jun-2023 | Corporate Asset Purchase | Buildings and Property | ||
| Healion Bio | 02-Feb-2023 | Merger/Acquisition | Drug Discovery | ||
| Southern Research (Infectious Disease R&D Facility in Frederick, Maryland) | 04-Oct-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Katana Pharmaceuticals (Assets Related To Insulin Resistance in Chatham, New Jersey) | 22-Dec-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Trigemina (Non-Addictive Migraine and Pain Treatment Programs in Moraga, California) | 11-Jun-2020 | Corporate Asset Purchase | Buildings and Property |
Tonix Pharmaceuticals Holding ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.12 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Tonix Pharmaceuticals Holding FAQs
-
When was Tonix Pharmaceuticals Holding founded?
Tonix Pharmaceuticals Holding was founded in 2007.
-
Where is Tonix Pharmaceuticals Holding headquartered?
Tonix Pharmaceuticals Holding is headquartered in Chatham, NJ.
-
What is the size of Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding has 142 total employees.
-
What industry is Tonix Pharmaceuticals Holding in?
Tonix Pharmaceuticals Holding’s primary industry is Drug Discovery.
-
Is Tonix Pharmaceuticals Holding a private or public company?
Tonix Pharmaceuticals Holding is a Public company.
-
What is Tonix Pharmaceuticals Holding’s stock symbol?
The ticker symbol for Tonix Pharmaceuticals Holding is TNXP.
-
What is the current stock price of Tonix Pharmaceuticals Holding?
As of 16-Nov-2026 the stock price of Tonix Pharmaceuticals Holding is $2.88.
-
What is the current market cap of Tonix Pharmaceuticals Holding?
The current market capitalization of Tonix Pharmaceuticals Holding is $56M.
-
What is Tonix Pharmaceuticals Holding’s current revenue?
The trailing twelve month revenue for Tonix Pharmaceuticals Holding is $43M.
-
Who are Tonix Pharmaceuticals Holding’s competitors?
Seres Therapeutics, Cognition Therapeutics, Alector, Neurelis, and Dogwood Therapeutics are some of the 38 competitors of Tonix Pharmaceuticals Holding.
-
What is Tonix Pharmaceuticals Holding’s annual earnings per share (EPS)?
Tonix Pharmaceuticals Holding’s EPS for 12 months was -$12.22.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process